Case Study: Driving Analytical Robustness & CMC Readiness for Efficient Development of Novel RNA Modalities
- Navigating unique analytical and regulatory challenges when developing novel RNA-based vaccines
- Designing phase-appropriate QC and analytical strategies that can adapt as novel modalities progress toward GMP readiness
- How learnings from novel platforms can inform broader industry best practices in analytical robustness and CMC submissions